Clearpoint Neuro, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Clearpoint Neuro, Inc. on February 14, 2022, reporting events occurring on February 9, 2022. The Company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol CLPT. The filing primarily addresses the voluntary resignation of an executive officer.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figures disclosed relate to the compensatory arrangements for the departing executive:
- Separation Payment: $5,000 payable in cash.
- Consulting Fee: $10,000 per month, payable in arrears, for a minimum of two months (extendable up to two years).
- Equity: Previously granted stock options and restricted stock will continue to vest according to their original time-based schedules.
Material Changes
The material change reported is the departure of Peter G. Piferi, who resigned as Chief Operating Officer effective February 18, 2022. The Company states that the resignation is not the result of any disagreement with management or the Company's operations. Mr. Piferi will transition to an independent contractor role to assist with the handover of his responsibilities.
Outlook, Risks, and Management Commentary
Management commentary is limited to the terms of the separation. Mr. Piferi will provide consulting services during a "Transition Period" starting February 21, 2022. As a condition of receiving the separation payments and benefits, Mr. Piferi must execute a general release of all claims against the Company. No specific risks, contingencies, or forward-looking guidance regarding the Company's business operations are provided in this filing.
Key Facts for Investor Verification
- Verify the effective date of the COO departure (February 18, 2022) and the start of the consulting arrangement (February 21, 2022).
- Confirm the total potential cost of the consulting agreement, which could extend up to two years at $10,000 per month.
- Review the full text of the Confidential Resignation Agreement (Exhibit 10.1) and Independent Contractor Agreement (Exhibit 10.2) for specific restrictive covenants and conditions.
- Note that this filing contains no operational or financial performance data; refer to the most recent 10-K or 10-Q for financial health metrics.